Industry, FDA, Friends focus on data needed to speed up development of gene and cell therapies

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

On May 30, an international coalition announced the launch of CAR T Vision, a coalition that aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.

May 30, 2025

Vol.51 No.21

In Brief

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Nadeem R. Abu-RustumLouis Burt NaborsMichael J. StylerJames ThompsonErin HeslerNadeem R. Abu-Rustum, Louis Burt Nabors, Michael J. Styler, and James Thompson were recognized by the National Comprehensive Cancer Network as its 2025 awardees who “go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.”

May 30, 2025

Vol.51 No.21

In Brief

KU Cancer Center breaks ground for new complex

The University of Kansas Cancer Center broke ground on the future site of a new complex on May 22 that will bring research and patient care into one area for the first time in KU Cancer Center’s history.

May 30, 2025

Vol.51 No.21

Drugs & Targets

FDA grants priority review for sevabertinib in HER2-mutant NSCLC

FDA accepted a new drug application and granted priority review designation for the investigational compound sevabertinib (BAY 2927088), an oral, small molecule, tyrosine kinase inhibitor, for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have activating human epidermal growth factor receptors 2 (HER2) (ERBB2) mutations and who have received a prior systemic therapy.

May 30, 2025

Vol.51 No.21

Drugs & Targets

Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer

Alligator Bioscience on May 26 announced that the European Commission granted orphan drug designation to HLX22, an anti-HER2 monoclonal antibody, for the treatment of gastric cancer. HLX22 is being developed by Shanghai Henlius Biotech, Inc. under a sublicense from AbClon, Inc., which had previously licensed the antibody from Alligator.

May 30, 2025

Vol.51 No.21

Podcast

In The Headlines: Back to “business as usual” at FDA?

The Oncologic Drugs Advisory Committee held its first session since President Trump’s inauguration, with a two-day, back-to-back marathon meeting, signaling a return to business at FDA after significant upheaval at the agency.

May 28, 2025

Vol.51 No.20

Industry, FDA, Friends focus on data needed to speed up development of gene and cell therapies

YOU MAY BE INTERESTED IN

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

KU Cancer Center breaks ground for new complex

FDA grants priority review for sevabertinib in HER2-mutant NSCLC

Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer

In The Headlines: Back to “business as usual” at FDA?

Renew today!

Subscriber content

Never miss an issue!

Login